Suppr超能文献

[坏疽性脓皮病的治疗现状与最新进展]

[Current situation and the latest progress in the treatment of pyoderma gangrenosum].

作者信息

Li Y, Wang Y Y, Xing K, Li S S

机构信息

Department of Dermatology, the First Hospital of Jilin University, Changchun 130021, China.

出版信息

Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi. 2022 Jun 20;38(6):574-579. doi: 10.3760/cma.j.cn501225-20220330-00108.

Abstract

Pyoderma gangrenosum (PG) is a rare chronic inflammatory non-infectious skin dermatosis, and there is no clear treatment guideline for this disease at home and abroad. There are a variety of clinical treatment methods for PG, including local therapy and systemic application of glucocorticoids, immunosuppressants, intravenous immuno- globulin, and biologics. Glucocorticoids are the first-line drugs commonly used in clinical practice, and immunosuppressants can be used alone or in combination with glucocorticoids. In recent years, more and more evidence has shown that biologics are a new trend in the treatment of PG, mainly including tumor necrosis factor α inhibitors, interleukin-1 (IL-1) inhibitors, IL-12/23 inhibitors, IL-17 inhibitors, rituximab, and small molecular inhibitors. This article summarizes the current status and latest progress in the treatment of PG, hoping to provide clinicians with ideas for the treatment of PG.

摘要

坏疽性脓皮病(PG)是一种罕见的慢性炎症性非感染性皮肤病,国内外尚无针对该病的明确治疗指南。PG有多种临床治疗方法,包括局部治疗以及全身应用糖皮质激素、免疫抑制剂、静脉注射免疫球蛋白和生物制剂。糖皮质激素是临床常用的一线药物,免疫抑制剂可单独使用或与糖皮质激素联合使用。近年来,越来越多的证据表明生物制剂是PG治疗的新趋势,主要包括肿瘤坏死因子α抑制剂、白细胞介素-1(IL-1)抑制剂、IL-12/23抑制剂、IL-17抑制剂、利妥昔单抗和小分子抑制剂。本文总结了PG治疗的现状和最新进展,希望为临床医生治疗PG提供思路。

相似文献

1
[Current situation and the latest progress in the treatment of pyoderma gangrenosum].
Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi. 2022 Jun 20;38(6):574-579. doi: 10.3760/cma.j.cn501225-20220330-00108.
3
Anti-IL 17 biologics and pyoderma gangrenosum - therapeutic or causal?
Arch Dermatol Res. 2025 Jan 13;317(1):235. doi: 10.1007/s00403-024-03689-4.
4
Biologic and small-molecule medications in the management of pyoderma gangrenosum.
J Dermatolog Treat. 2019 May;30(3):264-276. doi: 10.1080/09546634.2018.1506083. Epub 2018 Sep 7.
5
PAPA Syndrome: Challenges in Achieving Long-Term Remission.
Acta Dermatovenerol Croat. 2023 Nov;31(2):106-109.
6
Diagnosis and novel clinical treatment strategies for pyoderma gangrenosum.
Expert Rev Clin Pharmacol. 2020 Feb;13(2):157-161. doi: 10.1080/17512433.2020.1709825. Epub 2020 Jan 6.
7
Tofacitinib therapy for severe pyoderma gangrenosum in a patient with enteropathic arthritis: a case-based review.
Rheumatol Int. 2024 Oct;44(10):2227-2237. doi: 10.1007/s00296-024-05560-1. Epub 2024 Mar 15.
8
Pyoderma Gangrenosum and Interleukin Inhibitors: A Semi-Systematic Review.
Dermatology. 2022;238(4):785-792. doi: 10.1159/000519320. Epub 2021 Oct 28.
9
Clinical characteristics of pyoderma gangrenosum: Case series and literature review.
Medicine (Baltimore). 2024 Sep 13;103(37):e39634. doi: 10.1097/MD.0000000000039634.
10
The safety of treatments used in pyoderma gangrenosum.
Expert Opin Drug Saf. 2018 Jan;17(1):55-61. doi: 10.1080/14740338.2018.1396316. Epub 2017 Oct 27.

引用本文的文献

1
Clinical characteristics, treatment, and wound management of pyoderma gangrenosum: A case series.
PLoS One. 2025 Jun 23;20(6):e0326203. doi: 10.1371/journal.pone.0326203. eCollection 2025.
2
[Emphasis on multidisciplinary collaboration in clinical diagnosis and treatment of autoimmune disease-related ulcers].
Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi. 2022 Jun 20;38(6):501-505. doi: 10.3760/cma.j.cn501120-20211112-00385.

本文引用的文献

1
Combination Immunotherapy Use and Withdrawal in Pediatric Inflammatory Bowel Disease-A Review of the Evidence.
Front Pediatr. 2021 Sep 21;9:708310. doi: 10.3389/fped.2021.708310. eCollection 2021.
2
Successful treatment of ulcerated pyoderma gangrenosum with baricitinib, a novel JAK inhibitor.
J Transl Autoimmun. 2021 Apr 15;4:100099. doi: 10.1016/j.jtauto.2021.100099. eCollection 2021.
3
Tofacitinib for the treatment of refractory pyoderma gangrenosum.
Clin Exp Dermatol. 2021 Aug;46(6):1082-1085. doi: 10.1111/ced.14683. Epub 2021 May 29.
4
Vulvovaginal pyoderma gangrenosum associated with rituximab use in 2 patients with rheumatoid arthritis.
JAAD Case Rep. 2021 Feb 23;10:75-77. doi: 10.1016/j.jdcr.2021.02.013. eCollection 2021 Apr.
5
Certolizumab for the treatment of localized pyoderma gangrenosum associated with Crohn's disease: A case report.
Dermatol Ther. 2020 Nov;33(6):e14352. doi: 10.1111/dth.14352. Epub 2020 Oct 5.
6
[Theories and strategies of chronic wound treatment].
Zhonghua Shao Shang Za Zhi. 2020 Sep 20;36(9):798-802. doi: 10.3760/cma.j.cn501120-20200728-00361.
7
Refractory steroid-resistant pyoderma gangrenosum successfully treated with intravenous immunoglobulins.
Dermatol Ther. 2020 Nov;33(6):e14322. doi: 10.1111/dth.14322. Epub 2020 Oct 1.
8
Pyoderma gangrenosum: proposed pathogenesis and current use of biologics with an emphasis on complement C5a inhibitor IFX-1.
Expert Opin Investig Drugs. 2020 Nov;29(11):1179-1185. doi: 10.1080/13543784.2020.1819981. Epub 2020 Sep 29.
9
Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: Twenty-six-week phase 3 open-label study.
J Dermatol. 2020 Dec;47(12):1383-1390. doi: 10.1111/1346-8138.15533. Epub 2020 Aug 17.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验